Welcome to our dedicated page for NeurAxis news (Ticker: $NRXS), a resource for investors and traders seeking the latest updates and insights on NeurAxis stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NeurAxis's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NeurAxis's position in the market.
NeurAxis (NRXS), a medical technology company specializing in neuromodulation therapies for chronic conditions, will release its Q1 2024 financial results on May 22, 2024, before market open. The period covered is up to March 31, 2024. A conference call is scheduled for the same day at 9:00 am ET to review the results. NeurAxis has also filed a Form 12b-25, indicating a delay in filing its Form 10-Q, which is now expected to be filed on May 20, 2024.
The conference call can be accessed via a live webcast available in the Investor Relations section of NeurAxis' website, and replay options will be provided. Participants can submit questions through the webcast portal or by emailing NRXS@lythampartners.com.